Koninklijke Philips (NYSE:PHG) Stock Holdings Lowered by Mondrian Investment Partners LTD

Mondrian Investment Partners LTD reduced its stake in shares of Koninklijke Philips (NYSE:PHG) by 14.4% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 8,180,562 shares of the technology company’s stock after selling 1,372,496 shares during the period. Koninklijke Philips makes up 3.3% of Mondrian Investment Partners LTD’s holdings, making the stock its 4th biggest holding. Mondrian Investment Partners LTD’s holdings in Koninklijke Philips were worth $206,150,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of the stock. Wealth Enhancement Advisory Services LLC grew its stake in Koninklijke Philips by 6.9% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 60,365 shares of the technology company’s stock valued at $1,207,000 after purchasing an additional 3,891 shares in the last quarter. Principal Securities Inc. acquired a new stake in Koninklijke Philips during the 4th quarter valued at approximately $27,000. Corient Private Wealth LLC grew its stake in Koninklijke Philips by 21.0% during the 4th quarter. Corient Private Wealth LLC now owns 64,724 shares of the technology company’s stock valued at $1,510,000 after purchasing an additional 11,211 shares in the last quarter. Envestnet Portfolio Solutions Inc. grew its stake in Koninklijke Philips by 12.9% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 26,515 shares of the technology company’s stock valued at $668,000 after purchasing an additional 3,040 shares in the last quarter. Finally, OLD Mission Capital LLC grew its stake in Koninklijke Philips by 434.9% during the 4th quarter. OLD Mission Capital LLC now owns 434,282 shares of the technology company’s stock valued at $10,132,000 after purchasing an additional 353,096 shares in the last quarter. 13.67% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded Koninklijke Philips from a “hold” rating to a “buy” rating in a research note on Monday, July 15th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold”.

Koninklijke Philips Price Performance

Shares of NYSE PHG opened at $31.20 on Wednesday. The firm has a market cap of $29.32 billion, a PE ratio of -32.49, a price-to-earnings-growth ratio of 1.06 and a beta of 0.73. The business has a 50 day moving average price of $28.63 and a two-hundred day moving average price of $25.55. The company has a quick ratio of 0.74, a current ratio of 1.16 and a debt-to-equity ratio of 0.60. Koninklijke Philips has a fifty-two week low of $17.75 and a fifty-two week high of $31.50.

Koninklijke Philips (NYSE:PHG) last issued its earnings results on Monday, July 29th. The technology company reported $0.32 EPS for the quarter. The company had revenue of $4.80 billion during the quarter. Koninklijke Philips had a positive return on equity of 10.15% and a negative net margin of 2.35%. Sell-side analysts expect that Koninklijke Philips will post 1.5 earnings per share for the current fiscal year.

Koninklijke Philips Company Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.